

Post Menopausal Osteoporosis R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/P9893F07621BEN.html>

Date: October 2020

Pages: 132

Price: US\$ 1,699.00 (Single User License)

ID: P9893F07621BEN

Abstracts

Post Menopausal Osteoporosis Pipeline Overview

The Q4 Post Menopausal Osteoporosis pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Post Menopausal Osteoporosis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Post Menopausal Osteoporosis Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Post Menopausal Osteoporosis disease overview, Post Menopausal Osteoporosis types, Post Menopausal Osteoporosis symptoms, causes, and FDA/EMA approved treatment options.

Post Menopausal Osteoporosis Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Post Menopausal Osteoporosis indication. The report presents near-term and long-term pipeline development trends and potential insights.

Post Menopausal Osteoporosis Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 24 companies. Business profiles and contact details of the companies actively perusing Post Menopausal Osteoporosis pipeline are assessed.

Post Menopausal Osteoporosis R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Post Menopausal Osteoporosis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Post Menopausal Osteoporosis companies look for licensing and collaboration partners

High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Post Menopausal Osteoporosis pipeline development companies.

Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Post Menopausal Osteoporosis Pipeline Market News and Developments during 2020
The Post Menopausal Osteoporosis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Post Menopausal Osteoporosis Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Post Menopausal Osteoporosis pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new

molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and investment details of companies are included

24 companies are included including Ablynx NV, AlphaMab Co Ltd, Amgen Inc, Aryogen Pharmed Co, Entera Bio Ltd, Enteris BioPharma Inc, Enzene Biosciences Ltd, Epygen Biotech Pvt Ltd, Genor BioPharma Co Ltd, Hualan Biological Engineering Inc, Intas Pharmaceuticals Ltd, Ipsen SA, JHL Biotech Inc, Jiangsu T-mab BioPharma Co Ltd, Lupin Ltd, Luye Pharma Group Ltd, Nano Intelligent Biomedical Engineering Corp, Nanomedic Inc, Paras Biopharmaceuticals Finland Oy, Qilu Pharmaceutical Co Ltd, Reliance Life Sciences Pvt Ltd, Sandoz International GmbH, Shenzhen Salubris Pharmaceuticals Co Ltd, Uni-Bio Science Group Ltd,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Post Menopausal Osteoporosis pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition

opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. POST MENOPAUSAL OSTEOPOROSIS PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Post Menopausal Osteoporosis Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Post Menopausal Osteoporosis Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Post Menopausal Osteoporosis pipeline
- 2.5 Active Companies Developing Post Menopausal Osteoporosis pipeline

3. POST MENOPAUSAL OSTEOPOROSIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. POST MENOPAUSAL OSTEOPOROSIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 Ablynx NV
 - AlphaMab Co Ltd
 - Amgen Inc
 - Aryogen Pharmed Co
 - Entera Bio Ltd
 - Enteris BioPharma Inc
 - Enzene Biosciences Ltd
 - Epygen Biotech Pvt Ltd
 - Genor BioPharma Co Ltd
 - Hualan Biological Engineering Inc
 - Intas Pharmaceuticals Ltd
 - Ipsen SA
 - JHL Biotech Inc

Jiangsu T-mab BioPharma Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Nano Intelligent Biomedical Engineering Corp
Nanomedic Inc
Paras Biopharmaceuticals Finland Oy
Qilu Pharmaceutical Co Ltd
Reliance Life Sciences Pvt Ltd
Sandoz International GmbH
Shenzhen Salubris Pharmaceuticals Co Ltd
Uni-Bio Science Group Ltd

5. POST MENOPAUSAL OSTEOPOROSIS PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. POST MENOPAUSAL OSTEOPOROSIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

7.1 About the Publisher

7.2 Sources and Research Methodology

I would like to order

Product name: Post Menopausal Osteoporosis R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/P9893F07621BEN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9893F07621BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970